Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) major shareholder John D. Halpern acquired 335,920 shares of the stock in a transaction on Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, for a total transaction of $1,101,817.60. Following the acquisition, the insider now directly owns 450,961 shares in the company, valued at approximately $1,479,152.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Eterna Therapeutics Trading Up 4.7 %
Shares of NASDAQ:ERNA opened at $4.67 on Thursday. Eterna Therapeutics Inc. has a 12 month low of $2.73 and a 12 month high of $127.60.
Get Eterna Therapeutics alerts:About Eterna Therapeutics
(Get Rating)
Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.Recommended Stories
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.